← Back to Search

BAC Feedback for Drunk Driving

N/A
Waitlist Available
Research Sponsored by University of Missouri-Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial tests how well people make decisions about driving after drinking alcohol. People will drink alcohol in a lab, then be monitored for 6 weeks to see how often they drive after drinking.

Who is the study for?
This trial is for English-speaking moderate to heavy drinkers who regularly drive and have engaged in recent binge drinking. It's not suitable for individuals with a BMI under 30, those with health conditions that make alcohol consumption unsafe, or people currently treated for substance use or psychiatric disorders.Check my eligibility
What is being tested?
The study examines decision-making in drunk driving by comparing two groups: one receives feedback/warnings about their Blood Alcohol Content (BAC), while the other does not. Participants undergo lab sessions followed by six weeks of mobile assessment after drinking events.See study design
What are the potential side effects?
Since this trial involves alcohol consumption, potential side effects may include typical reactions to alcohol such as impaired coordination, dizziness, nausea, hangover symptoms, and potentially more severe consequences if participants choose to drive.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Alcohol impaired driving behavior
Alcohol impaired driving behavior (retrospective)
Alcohol impaired driving intentions
Secondary outcome measures
Perceived risk of driving

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: BAC Feedback, immediate onsetExperimental Treatment1 Intervention
Participants will receive a"BAC Feedback/Warning" intervention based on their assessed BAC. Participants in this arm will have a warning presented on their smartphone when they provide a breath sample that indicated their BAC has reached a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive. In this condition, participants will start their 6 week AA portion of their participation immediately after their laboratory session, and will be followed for 6 weeks afterwards. Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the "BAC Feedback/Warning" intervention.
Group II: BAC Feedback, delayed onsetExperimental Treatment1 Intervention
Participants will receive the "BAC Feedback/Warning" intervention based on their assessed BAC during drinking events.The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive. In this condition, participants will be followed for 6 weeks after their laboratory session prior to starting their 6 week AA portion of their participation. Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the "BAC Feedback/Warning" intervention.
Group III: Minimal Assessment ControlPlacebo Group1 Intervention
Participants will receive the "No BAC Feedback/Warning" intervention. Participants in this condition will complete the laboratory and interview portions of the project. However the AA portion of the project will not contain warning about their BAC (No BAC Feedback/Warning) and will ask fewer questions regarding their AID decisions. The role of this condition is to provide a baseline comparison of AID behavior for the two active assessment conditions.

Find a Location

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor
367 Previous Clinical Trials
628,187 Total Patients Enrolled
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
815 Previous Clinical Trials
1,159,641 Total Patients Enrolled
2 Trials studying Drunk Driving
7,718 Patients Enrolled for Drunk Driving

Media Library

BAC feedback/warning Clinical Trial Eligibility Overview. Trial Name: NCT03846050 — N/A
Drunk Driving Research Study Groups: BAC Feedback, immediate onset, BAC Feedback, delayed onset, Minimal Assessment Control
Drunk Driving Clinical Trial 2023: BAC feedback/warning Highlights & Side Effects. Trial Name: NCT03846050 — N/A
BAC feedback/warning 2023 Treatment Timeline for Medical Study. Trial Name: NCT03846050 — N/A
~36 spots leftby Jun 2025